AbbVie
ABBV
3,390 hedge funds and large institutions have $228B invested in AbbVie in 2024 Q1 according to their latest regulatory filings, with 220 funds opening new positions, 1,338 increasing their positions, 1,495 reducing their positions, and 113 closing their positions.
95% more first-time investments, than exits
New positions opened: 220 | Existing positions closed: 113
39% more capital inflows, than outflows
Capital inflows: $10.5B | Capital outflows: $7.54B
29% more call options, than puts
Call options by funds: $3.29B | Put options by funds: $2.55B
10% more funds holding in top 10
Funds holding in top 10: 202 → 223 (+21)
2% more funds holding
Funds holding: 3,332 → 3,390 (+58)
0.66% more ownership
Funds ownership: 70.46% → 71.12% (+0.66%)
11% less repeat investments, than reductions
Existing positions increased: 1,338 | Existing positions reduced: 1,495
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Vanguard Group
Malvern,
Pennsylvania
|
+$1.72B |
| 2 |
Franklin Resources
San Mateo,
California
|
+$616M |
| 3 |
Capital World Investors
Los Angeles,
California
|
+$538M |
| 4 |
Capital International Investors
Los Angeles,
California
|
+$536M |
| 5 |
DZ Bank
Frankfurt Am Main,
Germany
|
+$397M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Pacer Advisors
Malvern,
Pennsylvania
|
-$423M |
| 2 |
Bank of New York Mellon
New York
|
-$391M |
| 3 |
Assenagon Asset Management
Senningerberg,
Luxembourg
|
-$315M |
| 4 |
Charles Schwab
San Francisco,
California
|
-$299M |
| 5 |
Goldman Sachs
New York
|
-$299M |
ABBV Hedge Fund Activity: Q1 2024 in Review
3,390 of the 6,966 institutional investors tracked by Wall St. Rank reported a position in AbbVie (ABBV) for Q1 2024, worth a combined $228B — up 18% from $193B a quarter earlier.
Buyers outnumbered sellers: 220 funds opened new ABBV positions and 113 closed out — a net gain of 107 holders — while 1,338 added to existing stakes and 1,495 trimmed.
The largest buyer was Vanguard Group, adding an estimated $1.72B. The largest seller was Pacer Advisors, cutting an estimated $423M.
- 3,390 institutional investors held AbbVie (ABBV) as of Q1 2024, up from 3,332 in Q4 2023.
- Funds reported $228B of AbbVie stock for Q1 2024, up 18% quarter-over-quarter.
- 220 funds opened new AbbVie positions in Q1 2024 and 113 closed out, a net change of +107 holders.
- The largest AbbVie buyer in Q1 2024 was Vanguard Group, an estimated $1.72B added.
- The largest AbbVie seller in Q1 2024 was Pacer Advisors, an estimated $423M sold.
Based on aggregated 13F filings for Q1 2024.